269 related articles for article (PubMed ID: 34530020)
1. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.
Gevaert P; Saenz R; Corren J; Han JK; Mullol J; Lee SE; Ow RA; Zhao R; Howard M; Wong K; Islam L; Ligueros-Saylan M; Omachi TA; Bachert C
J Allergy Clin Immunol; 2022 Mar; 149(3):957-965.e3. PubMed ID: 34530020
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
[TBL] [Abstract][Full Text] [Related]
3. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis.
Damask C; Chen M; Holweg CTJ; Yoo B; Millette LA; Franzese C
Am J Rhinol Allergy; 2022 Jan; 36(1):135-141. PubMed ID: 34382434
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.
Gevaert P; Mullol J; Saenz R; Ko J; Steinke JW; Millette LA; Meltzer EO
Ann Allergy Asthma Immunol; 2024 Mar; 132(3):355-362.e1. PubMed ID: 37951571
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
6. NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps.
Sindwani R; Han JK; Soteres DF; Messina JC; Carothers JL; Mahmoud RA; Djupesland PG
Am J Rhinol Allergy; 2019 Jan; 33(1):69-82. PubMed ID: 30477309
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
8. The role of omalizumab in the treatment of chronic rhinosinusitis with nasal polyposis.
Aldinger JP; Dobyns T; Lam K; Han JK
Expert Opin Biol Ther; 2021 Sep; 21(9):1143-1149. PubMed ID: 34334061
[No Abstract] [Full Text] [Related]
9. Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER).
Gevaert P; Bachert C; Maspero JF; Cuevas M; Steele D; Acharya S; Altman P
J Allergy Clin Immunol; 2022 May; 149(5):1675-1682.e3. PubMed ID: 35094848
[TBL] [Abstract][Full Text] [Related]
10. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
Peters AT; Han JK; Hellings P; Heffler E; Gevaert P; Bachert C; Xu Y; Chuang CC; Neupane B; Msihid J; Mannent LP; Guyot P; Kamat S
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2461-2471.e5. PubMed ID: 33548517
[TBL] [Abstract][Full Text] [Related]
11. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.
Bachert C; Mannent L; Naclerio RM; Mullol J; Ferguson BJ; Gevaert P; Hellings P; Jiao L; Wang L; Evans RR; Pirozzi G; Graham NM; Swanson B; Hamilton JD; Radin A; Gandhi NA; Stahl N; Yancopoulos GD; Sutherland ER
JAMA; 2016 Feb; 315(5):469-79. PubMed ID: 26836729
[TBL] [Abstract][Full Text] [Related]
12. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
Wu Q; Zhang Y; Kong W; Wang X; Yuan L; Zheng R; Qiu H; Huang X; Yang Q
Int Arch Allergy Immunol; 2022; 183(3):279-288. PubMed ID: 34607329
[TBL] [Abstract][Full Text] [Related]
13. Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study.
Armengot-Carceller M; Gómez-Gómez MJ; García-Navalón C; Doménech-Campos E; Muñoz-Fernández N; Miguel AG; Marco-Algarra J; Palop-Cervera M; Piñero AG
Am J Rhinol Allergy; 2021 Jul; 35(4):516-524. PubMed ID: 33153272
[TBL] [Abstract][Full Text] [Related]
14. NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis.
Leopold DA; Elkayam D; Messina JC; Kosik-Gonzalez C; Djupesland PG; Mahmoud RA
J Allergy Clin Immunol; 2019 Jan; 143(1):126-134.e5. PubMed ID: 29928924
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials.
Wu Q; Yuan L; Qiu H; Wang X; Huang X; Zheng R; Yang Q
BMJ Open; 2021 Sep; 11(9):e047344. PubMed ID: 34479933
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
Bachert C; Han JK; Desrosiers MY; Gevaert P; Heffler E; Hopkins C; Tversky JR; Barker P; Cohen D; Emson C; Martin UJ; Shih VH; Necander S; Kreindler JL; Jison M; Werkström V
J Allergy Clin Immunol; 2022 Apr; 149(4):1309-1317.e12. PubMed ID: 34599979
[TBL] [Abstract][Full Text] [Related]
17. [Short-term efficacy of anti-IgE monoclonal antibody in patients with recurrent chronic rhinosinusitis with nasal polyps combined with asthma].
Shen S; Lou HF; Yan B; Wang Y; Cao FF; Xiong W; Wang CS; Zhang L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 Oct; 56(10):1035-1041. PubMed ID: 34666463
[No Abstract] [Full Text] [Related]
18. Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
Geng B; Dilley M; Anterasian C
Curr Allergy Asthma Rep; 2021 Jun; 21(6):36. PubMed ID: 34110505
[TBL] [Abstract][Full Text] [Related]
19. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.
Desrosiers M; Diamant Z; Castelnuovo P; Hellings PW; Han JK; Peters AT; Silver J; Smith SG; Fuller A; Sousa AR; Chan RH; Gevaert P;
Int Forum Allergy Rhinol; 2024 Jan; 14(1):18-31. PubMed ID: 37345861
[TBL] [Abstract][Full Text] [Related]
20. The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye.
Demir M; Tunakan Dalgic C; Mete Gokmen EN; Savas R; Eroglu S; Ozden G; Orcen C; Pacaci Cetin G; Arslan B; Bilgir F; Bulut G; Akcam NY; Ozgul S; Cerci P; Coskun R; Gode S; Yilmaz I; Sin AZ
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541174
[No Abstract] [Full Text] [Related]
[Next] [New Search]
